Dr. Sagar Parikh, John F. Greden Professor of Depression and Clinical Neuroscience, and Professor of Psychiatry at the University of Michigan, discusses topline results from Sage and Biogen’s Phase 3 CORAL Study evaluating zuranolone, a once-daily, two-week, investigational drug in development for the treatment of major depressive disorder (MDD).
Dr. Benjamin Lowentritt, MD, FACS, Director, Minimally Invasive Surgery and Robotics and Cancer Care Program at Chesapeake Urology and an investigator on the ERLEADA ® (apalutamide) real-world study discusses the findings that showed a more than 90 percent decline in prostate-specific antigen (PSA) at six months in a majority of patients with mCSPC, reinforcing the positive results found in the clinical trial setting. The patient-reported outcomes study demonstrated that rapid and deep PSA decline is associated with improved health-related quality of life in advanced prostate cancer. These data were presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium 2022.
John Glasspool, CEO of Anthos Therapeutics discusses their lead product, abelacimab, an anticoagulant in development for the prevention of thrombosis. Because of its unique mechanism of action with dual activity against Factor XI and Factor XIa, abelacimab provides reliable and safe anticoagulation without the fear of bleeding that has caused many doctors to stay away from traditional anticoagulants.
Dr. Priya Kishnani, MD, Chen Family Professor of Pediatrics, Chief of the Division of Medical Genetics at Duke University Medical Center and Medical Director of the YT and Alice Chen Pediatrics Genetics and Genomics Center discusses recent data on Sanofi‘s Nexviazyme ® (avalglucosidase alfa) that was presented at 18th annual WORLDSymposium™ which showed sustained improvements in respiratory function and mobility in patients with Pompe disease.
Dr. Yolanda Lawson, MD, Board Certified OB/GYN and Associate Attending at Baylor University Medical Center discusses cervical cancer which typically develops from human papillomavirus (HPV) and is highly preventable and treatable. She talks about why black women are dying at 1.5 times the rate of white women and what women should know and potentially do.
Investigator, Dr. Shambhu Aryal, MD, FCCP, Medical Director, Lung Transplant Program and Director, Inova Sarcoidosis Center, Inova Medical Group discusses the results of the ALARM study, led by the National Institutes of Health (NIH) and published in the “Journal of Heart and Lung Transplantation” that validated the ability of CareDx’s AlloSure ® Lung to detect signs of organ rejection and infection in asymptomatic lung transplant recipients in a real-world, home-based surveillance setting. The study also showed that AlloSure Lung identified episodes of acute rejection and infection that would have been missed using a biopsy strategy alone.
Dr. Martin Kolb, Director of the Division of Respirology at the Department of Medicine at McMaster University and an expert on interstitial lung disease discusses Horizon Therapeutics‘ Phase 2b pivotal trial to evaluate HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with idiopathic pulmonary fibrosis (IPF), the most common interstitial lung disease
Dr. Elizabeth Holt, MD, FACE, Head of Global Medical, Clinical, and Safety at LifeScan, a global leader in glucose monitoring and diabetes management, discusses how digital health solutions enhance the patient/physician relationship, and how cloud-connected devices can improve clinical outcomes. She talks about digital health and how it’s redefining chronic disease management, what physicians need to know now, and how to support the reluctant patient who has not embraced digital health solutions.
Dr. Allitia DiBernardo, M.D., Vice President, Global Medical Affairs, Neuroscience, Global Commercial Strategy Organization (GCSO) at Janssen discusses a novel patient recruitment strategy for patients with multiple sclerosis that was presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS ®) 2022 meeting. Janssen will be utilizing up-front matching to assign patients treatments as if they were being randomized to treatment. This unique design tactic is especially of value for studies whose results become part of the evidence for regulatory decision-making to be more credible with the potential for significant cost efficiencies in generating the data.
Dr. Axel Dignass, M.D., Ph.D., Head of the Department of Medicine I and Professor of Medicine and Gastroenterology at the Agaplesion Markus Hospital, Goethe University in Frankfurt and lead study investigator discusses findings from the Phase 2b QUASAR trial evaluating TREMFYA ® (guselkumab) in ulcerative colitis (UC). More than 60% of adults with moderately to severely active UC achieved clinical response with TREMFYA at week 12, the study’s primary endpoint. More than 30% of patients showed endoscopic improvement with TREMFYA at the same timepoint. These data were presented at the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO) 2022 meeting.